CVS Health (NYSE:CVS) Given New $95.00 Price Target at Bank of America

CVS Health (NYSE:CVS) had its price objective decreased by Bank of America from $100.00 to $95.00 in a research note published on Tuesday,Benzinga reports. Bank of America currently has a buy rating on the pharmacy operator’s stock.

A number of other research firms have also recently issued reports on CVS. Royal Bank Of Canada reiterated an “outperform” rating on shares of CVS Health in a report on Thursday, December 4th. Robert W. Baird upped their price target on CVS Health from $82.00 to $92.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 10th. Wall Street Zen downgraded shares of CVS Health from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. The Goldman Sachs Group raised their target price on shares of CVS Health from $93.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Finally, Sanford C. Bernstein restated a “market perform” rating and set a $91.00 price objective on shares of CVS Health in a research note on Tuesday, January 6th. Twenty analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.86.

CVS Health Stock Down 13.8%

Shares of CVS Health stock opened at $72.28 on Tuesday. CVS Health has a 1 year low of $53.36 and a 1 year high of $85.15. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. The company has a market capitalization of $91.75 billion, a P/E ratio of 190.21, a price-to-earnings-growth ratio of 0.77 and a beta of 0.48. The business has a 50-day moving average of $79.05 and a two-hundred day moving average of $75.02.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.24. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The business had revenue of $102.87 billion during the quarter, compared to analysts’ expectations of $98.85 billion. During the same period in the prior year, the business earned $1.09 EPS. CVS Health’s revenue for the quarter was up 7.8% compared to the same quarter last year. As a group, equities analysts predict that CVS Health will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Thursday, January 22nd will be paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date is Thursday, January 22nd. CVS Health’s dividend payout ratio is 700.00%.

Hedge Funds Weigh In On CVS Health

Institutional investors and hedge funds have recently modified their holdings of the stock. ORG Partners LLC boosted its holdings in shares of CVS Health by 418.9% during the second quarter. ORG Partners LLC now owns 467 shares of the pharmacy operator’s stock worth $32,000 after acquiring an additional 377 shares during the period. Sound Income Strategies LLC lifted its holdings in CVS Health by 32.3% during the 2nd quarter. Sound Income Strategies LLC now owns 2,774 shares of the pharmacy operator’s stock worth $191,000 after purchasing an additional 677 shares during the last quarter. GC Wealth Management RIA LLC boosted its stake in CVS Health by 34.3% in the 2nd quarter. GC Wealth Management RIA LLC now owns 9,053 shares of the pharmacy operator’s stock valued at $624,000 after purchasing an additional 2,312 shares during the period. Centennial Wealth Advisory LLC acquired a new position in CVS Health in the 2nd quarter valued at $519,000. Finally, Poinciana Advisors Group LLC increased its position in CVS Health by 51.1% during the 2nd quarter. Poinciana Advisors Group LLC now owns 5,036 shares of the pharmacy operator’s stock worth $347,000 after buying an additional 1,704 shares during the period. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Bank of America cut its price target from $100 to $95 but maintained a “buy” rating, signaling that at least some sell-side analysts still see meaningful upside from current levels. Benzinga: BofA lowers price target
• Positive Sentiment: Small insider purchase: EVP Steven H. Nelson bought 24 shares at about $53.70 per share on Jan. 23 — a symbolic sign of insider confidence, though the size is immaterial to valuation. SEC Form 4
• Positive Sentiment: Recent fundamentals remain supportive: CVS beat last-quarter revenue and EPS estimates and set FY2025 guidance of $6.55–$6.65, which underpins longer-term earnings expectations (a counterweight to today’s selloff).
• Neutral Sentiment: Analyst and media coverage is elevated (Zacks and other outlets flag CVS as a trending/covered stock), increasing attention and potential volatility but not a clear directional catalyst by itself. Zacks: Trending stock note
• Negative Sentiment: Policy shock: The Trump administration proposed keeping Medicare Advantage rates roughly flat (average increase ~0.09%), which directly pressures revenues for insurers and managed-care businesses tied to Medicare — a primary reason investors sold CVS today. Reuters: Medicare rate proposal
• Negative Sentiment: Market reaction: Multiple outlets report sharp broad sell-offs in insurers and CVS after the rate news, driving heavy volume and accelerating the decline. This is market-driven panic/liquidity selling rather than new company-specific operational news. CNBC: Health insurers tumble
• Negative Sentiment: Regulatory/legal risk: A House Judiciary report and related coverage accuse CVS of taking actions to limit competition among pharmacy hubs — this raises antitrust/regulatory risk that could mean fines, remedies, or stricter oversight. HealthcareDive: House Judiciary investigation
• Negative Sentiment: Additional press (Investing, Barron’s, FierceHealthcare) is amplifying both the Medicare-rate story and the antitrust allegations, increasing headline risk and likely keeping volatility elevated near-term. Barron’s: Medicare rates story

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.